Double-blind investigational anti-arrhythmic
Phase 2Small molecule
PfizerDouble-blind investigational anti-arrhythmic is one of 21 small molecule programs targeting Ventricular Tachycardia. It is currently in Phase 2.
1
Indications
1
Total Trials
0
Active Trials
20
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
32 competitors in Ventricular Tachycardia
#DrugCompanyPhaseTrials
1Bayer Aspirin
BayerApproved
Coreg
Akero TherapeuticsApproved
Calan
VVal Adams
Approved
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Tambocor
AAlvogen Korea
Approved
Mexitil
Boehringer IngelheimApproved
Adenocard
AstellasPhase 3
Drug Treatment
BBiosense Webster, Inc.
Approved
Cordarone
WWyeth-Lederle Vaccines
Phase 3
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]